Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study

Fig. 3

FEV1 assessments in Study 1222.6. (a) Trough FEV1 response weeks 1–4 from baseline (±SE), (b) FEV1 profile over time at week 4 from baseline (±SE) and (c) FEV1 AUC0–3 response weeks 1–4 from baseline (±SE). FEV1: forced expiratory volume in 1 s; SE: standard error; AUC0–3: area under the curve from 0–3 h

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us